CommercialPrior AuthHigh impact
Nipocalimab-aahu (Imaavy) (CPB 1083, reviewed 2026-08-11)
Aetna·Neurology, Internal Medicine·Medical Policy
Effective date
Aug 11, 2026
We identified it
Aug 16, 2026
Summary
Aetna has issued a new medical policy (CPB 1083, effective 2026-08-11) establishing coverage criteria for nipocalimab-aahu (Imaavy), a neonatal Fc receptor blocker for generalized myasthenia gravis. The policy requires precertification, neurologist prescription, and specific clinical criteria including antibody positivity, MGFA classification II-IV, MG-ADL score ≥5, and documented failure of at least two immunosuppressive therapies or one immunosuppressive therapy plus IVIG over 12 months. Billing teams must implement precertification requirements and ensure claims are submitted under HCPCS code J9256 only when all criteria are met.
Action Required
REQUIREMENTS:
— Immediately: Billing and precertification teams must register the new HCPCS code J9256 (nipocalimab-aahu injection, 3 mg) in the billing system for Commercial Aetna plans only. Configure system to flag claims for mandatory precertification before submission.
— Before 2026-08-11: Update precertification workflow to require prior authorization for all J9256 claims. Train staff to contact Aetna at (866) 752-7021 or fax (888) 267-3277 for precertification using Statement of Medical Necessity (SMN) forms available at Specialty Pharmacy Precertification portal.
— Before claim submission: Verify ALL of the following clinical criteria are met and documented by neurologist in patient record:
(1) Positive anti-AChR or anti-MuSK antibody test (CPT 0545U, 86041, 86042, 86043, or 86366)
(2) MGFA clinical classification II, III, or IV
(3) MG-ADL score ≥5
(4) Documentation of either: (a) failure of ≥2 immunosuppressive therapies over 12+ months, OR (b) failure of ≥1 immunosuppressive therapy AND IVIG over 12+ months, OR (c) documented clinical reason to avoid immunosuppressive/IVIG therapy
— Before billing: Verify patient is NOT concurrently using neonatal Fc receptor blockers (Rystiggo, Vyvgart, Vyvgart Hytrulo), complement inhibitors (Soliris, Ultomiris, Zilbrysq), or Uplizna. If documented, deny claim as per policy exclusions.
— For site of service: Reference Aetna's "Utilization Management Policy on Site of Care for Specialty Drug Infusions" to confirm approved infusion location before scheduling and billing (impacts CPT 96413-96417 administration codes).
— Ongoing: For continuation of therapy, require precertification for reauthorization claims demonstrating: (1) no unacceptable toxicity or disease progression, AND (2) positive clinical response documented by improved MG-ADL score, MMT, or MG Composite score.
— Consequence of inaction: Claims submitted without precertification or missing clinical criteria will be DENIED. Claims showing concurrent use of prohibited medications will be DENIED. Improper site of service billing may result in claim denials and audit liability.